Embecta ($EMBC) 2026 Guidance and Pen Needle Sales Case

• $EMBC investors filed a claim against Embecta for overstating the reliability of its 2026 guidance and the strength of its U.S. pen needle business.

• After Embecta reported weak second quarter results and cut its 2026 outlook, $EMBC fell 57% on May 5, 2026.

• $EMBC investors can join this case to be notified about potential recovery.

Case Details:

Between November 25, 2025 and May 4, 2026, Embecta told investors that its 2026 guidance remained in line with its long-term plan. Management repeatedly pointed to stable recurring revenue, a resilient product portfolio, and continued strength in pen needles, reinforcing confidence in the company’s outlook and execution.

However, during this same period, investors believed the company’s U.S. business was already under pressure. Embecta did not disclose that weakness in the U.S. pen needle market was likely to weigh on second-quarter and full-year 2026 results.

According to these claims, share loss, softer insulin pen demand, and ongoing pricing pressure were already affecting revenue, making the company’s 2026 guidance overly optimistic.

On May 5, 2026, the company reported that second-quarter revenue had declined 14.4% year over year and also lowered its full-year 2026 revenue guidance to $1.015 billion–$1.035 billion.

Following the update, $EMBC dropped 57.8%, closing at $3.90.

On May 6, 2026, analysts also highlighted a significant earnings miss, weak performance in the U.S. market, loss of pen needle share, and a sharp cut to guidance.

Based on these events, $EMBC investors filed a case against Embecta, stating that the company:

• Overstated the strength of its 2026 outlook.

• Failed to warn investors that U.S. pen needle sales were weakening.

• Caused investor losses after cutting guidance, which triggered a sharp market reaction.

Investors argue Embecta misled the market about its U.S. pen needle business and 2026 financial outlook, causing losses when the truth emerged.